Peak Activation Velocities and TREK-1 Channel Inhibition with PE-22-28

Journal Context: Neuropharmacology / ScienceDirect | Identifiers: DOI: 10.1016/j.neuropharm.2014.02.011 / PMID: 24583029

Principal Investigators: Mazarati, A., Djillani, A., Borsotto, M., Heurteaux, C., et al. (Institut de Pharmacologie Moléculaire et Cellulaire, CNRS, Sophia Antipolis, Valbonne, France)

Methodology: In vitro patch-clamp electrophysiology tracking of cloned human TREK-1 channels alongside in vivo behavioral modeling of mammalian groups subjected to forced swim and tail suspension stress paradigms. Subjects received standardized systemic and centralized infusions of PE-22-28 to map real-time behavioral change velocities.

Key Findings: Electro-physiological profiling verified that PE-22-28 binds to and blocks the TREK-1 potassium channel with extreme velocity and high affinity ($IC_{50} = 0.12\text{ nM}$). In living models, this targeted blockade translated into an immediate antidepressant response, drastically reducing immobility scores within a 4-day window. This represents a massive chronological upgrade over traditional monoaminergic antidepressants, which typically require 3 to 4 weeks to induce similar therapeutic neurochemical adaptations.